This presentation focuses on the rationale for selecting technologies that enable progression of poorly soluble compounds, based on compound's physical properties (e.g., melt and glass-transition temperatures, Log P) and product specifications (e.g. dose, pharmacokinetics, permeability). Predictive modelling and rapid screening best practices are also discussed, along with representative case studies demonstrating the parameters and rationale for choosing particle size reduction, solid dispersion or lipid-based approaches. To learn more, please view our presentation.
Latest content

Latest briefing from the Knowledge Center